Enpr-EMA, the network EMA coordinates to support paediatric medicine development across the EU, holds its annual open meeting online on . The day brings together investigators, sponsors, regulators and patient representatives on the questions that shape how paediatric trials get designed and evaluated — platform trials, biomarkers, and first-in-child development among them.
Dates and format
- Date: 5 November 2026, 09:00–16:30 CET
- Format: online, broadcast from the European Medicines Agency in Amsterdam
- Registration deadline: 19 October 2026
- Organizer: Enpr-EMA (European Network of Paediatric Research at EMA)
What it covers
EMA's published programme for the day covers platform trials, disease-progression models and biomarkers, patient partnership approaches, and patient experience in evidence generation, alongside best practices in paediatric clinical trials, public health emergency preparedness, and considerations specific to first-in-child and first-in-human development. It is EMA's main yearly forum for the paediatric research network it coordinates, not a vendor conference — the agenda runs on regulatory and scientific substance.
Who should attend
Sponsors and regulatory teams building or executing a paediatric investigation plan, clinical scientists designing first-in-child studies, and academic or patient-network participants already working within the Enpr-EMA network. The open format means a question raised live reaches the people who actually set paediatric regulatory expectations at EMA — a different proposition from reading the minutes afterward.
Tracking EU paediatric and AI policy together? The HMA/EMA AI and Data Forum runs the following week, and the full events directory lists everything we have verified.
Frequently asked questions
When is the EnprEMA 2026 annual open meeting?
Thursday, 5 November 2026, 09:00-16:30 Amsterdam time (CET), held online. EMA's own event page states these dates and times; register before 19 October 2026.
What is EnprEMA?
The European Network of Paediatric Research at EMA (Enpr-EMA) is the network EMA coordinates to support paediatric medicine development and clinical trials across the EU, bringing together research networks, investigators, sponsors, regulators and patient representatives.
What does the 2026 open meeting cover?
Per EMA's published programme, sessions cover platform trials, disease-progression models and biomarkers, patient partnership approaches, patient experience in evidence generation, and first-in-child and first-in-human development considerations, alongside best practices in paediatric clinical trials.
Is there a fee to attend?
EMA's own event page does not state a registration fee for the open meeting. We do not repeat pricing claims from third-party sites, so confirm directly with EMA when registering.
Who should attend?
Regulatory and clinical teams running or planning paediatric studies, sponsors preparing paediatric investigation plans, and anyone working on first-in-child development — the meeting is EMA's own open forum for exactly that audience, alongside academic and patient-network participants.
Sources & further reading
- European Medicines Agency. 2026 annual open meeting of the European Network of Paediatric Research at EMA (EnprEMA), 5 November 2026. ema.europa.eu
- European Medicines Agency. European Network of Paediatric Research at EMA (Enpr-EMA) — network overview. ema.europa.eu
Event details are published by the organizer and can change. Confirm dates, format and registration with EMA before making plans. Last verified 5 October 2026.
